BackFive Prime Therapeutics Overview

Five Prime Therapeutics Net Tangible Assets

Track Five Prime Therapeutics's net tangible assets ($270M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$265.10M
76.18% YoYΔ $114.63M vs prior year quarter

Peer average

Loading

Five Prime Therapeutics Net Tangible Assets History

Loading

Five Prime Therapeutics vs. peers: Net Tangible Assets Comparison

Loading

Five Prime Therapeutics Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Five Prime Therapeutics (FPRX) FAQ

The latest net tangible assets for FPRX is $270M as of December 2020. That compares with $150M in the prior-year period — up 76.2% year over year. Investors often review this figure alongside Five Prime Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FPRX's net tangible assets moved from $150M to $270M — a 76.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Five Prime Therapeutics's operating scale or balance-sheet position.

A net tangible assets figure of $270M for FPRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FPRX's net tangible assets ($270M), review year-over-year change from $150M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Five Prime Therapeutics's net tangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.